Compare Amphastar Pharmaceuticals Inc (AMPH) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Union Pacific Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Union Pacific Corporation trades at $291.52 (market cap $173.61B). The key difference: Union Pacific Corporation is far larger — about 200.9× Amphastar Pharmaceuticals Inc's market cap, and Union Pacific Corporation pays a 1.94% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | UNP | |
|---|---|---|
Market Cap | $863.95M | $173.61B |
Sector | Health | Industrials |
52-Week High | $30.81 | $307.32 |
52-Week Low | $16.87 | $214.91 |
Enterprise Value | $1.26B | $202.67B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Union Pacific (UNP) trades at $293.13, down 0.76% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with Q2 2026 EPS beating estimates at $3.41 versus $3.26 expected, while revenue growth and improved operating efficiency support management's raised full-year guidance. Recent dividend increases and institutional accumulation reflect confidence in the railroad operator's service-led growth strategy.
UNP presents a compelling investment case with 58.7% analyst buy ratings and a $334.33 consensus price target implying 14% upside. Key opportunities include pricing power, margin expansion, and domestic intermodal growth, while risks involve high fuel costs, regulatory scrutiny of the Norfolk Southern merger, and macroeconomic pressures on freight volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
